Genomic Databases Show European Ancestry Bias, Impacting Precision Oncology Equity
Genomic databases, crucial for precision oncology, are predominantly weighted towards individuals of European ancestry, according to panelists at a recent discussion. This imbalance creates significant gaps in germline data for underrepresented populations, hindering the effectiveness of precision medicine. For instance, while pathogenic variants in BRCA2 are common among breast cancer patients in Puerto Rico, germline variants associated with prostate cancer in the region are undertested. The lack of diverse data means that variants of unknown significance remain unclear for many subpopulations, making it difficult to share data appropriately and ensure equitable access to advanced cancer treatments. Texas Oncology, for example, observed a higher proportion of African American and Hispanic patients in a screening pilot for a KRAS G12C inhibitor trial, but these patients did not proceed to enrollment, highlighting systemic barriers.